20 de agosto de 2019
  • Lunes, 19 de Agosto
  • Viernes, 16 de Agosto
  • 23 de enero de 2014

    Zonegran® (zonisamide) Reimbursed in Switzerland as Monotherapy Treatment for Adults With Newly Diagnosed Partial Epilep


    - Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
    - Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc
    - Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, inflammatory bowel disease

    With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.

    For further information please visit our web site http://www.eisai.co.uk

    References

    [TAB]
    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 23 Ene. (7) - 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.
    [FTAB]

    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    Date of preparation: November 2013
    Job code: Zonegran-UK2515



    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com


    1) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
    October 2013)https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+...,+50,+100+mg+Hard+Capsules
    2) St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
    Initial Approach in Epilepsy Management (2009) &(2): 77-72
    3) ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in
    Europe 2010. Available
    at;http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010...
    (Accessed Feb 2013)
    4) EPI Swiss Epilepsy Centre. Available at:
    http://www.epi.ch/page.php?pages_id=301&language=fr (Accessed November 2013)
    5) French JA. Refractory Epilepsy; Clinical Overview. Epilepsia 2007: 48
    (Suppl1) 3 - 7.
    6) Baulac M. et al. M. Efficacy and tolerability of zonisamide versus
    controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3,
    randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 -
    588
    7) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
    and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    8) Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
    http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510...
    [http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] (Accessed December
    2013)
    9) Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A review with
    economic modeling. Epilepsia 2007; 48(12) 2224-2233.



    [TAB]
    Date of preparation: November 2013
    Job code: Zonegran-UK2515
    [FTAB]

    CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson/CharlotteAndrews, +44(0)7908 314 155/+44(0)7947 231 513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207 798 9262/+44 (0) 207 798 9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com